FSTL5 and hepatocellular carcinoma: Studies have shown an array of functions for FSTL5 in the human body, ranging from inhibiting the progression of hepatocellular carcinoma (Zhang et al. 2015, 2020; Li et al. 2018) to being a marker of poor prognosis in Non-WNT/Non-SHH medulloblastoma (Remke et al. 2011).